Navigation Links
Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
Date:8/27/2007

Quark's Novel siRNA Structures Exhibit Stability and Activity in vitro

FREMONT, Calif., Aug. 27 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced today that the Company has filed a patent application covering a number of novel chemical modifications that confer to the siRNA molecule stability and excellent penetration into the human cells tested.

"With the submission of this patent application, we believe we have provided significant additional protection for our pipeline program," said Daniel Zurr, President and CEO of Quark. "Filing of this patent application marks a significant step in our efforts to solidify our position as a leader in the RNAi therapeutics space, as the new structures allow us more flexibility with regard to intellectual property. We believe our future siRNA therapeutics will be less dependent on in-licensed rights to RNAi technology. This patent application adds the element of structural design to our expertise in identifying clinically attractive drug targets using a proprietary discovery platform and local or systemic delivery."

The patent application relates to new classes of chemically modified siRNA structures that have been tested in cell culture and have demonstrated enhanced stability, silencing activity, and cell penetration. Several new molecules are currently in preclinical testing. This research is part of Quark's program to develop novel synthetic siRNA patterns with drug-like properties as well as improved targeted delivery systems.

Currently, Quark owns or controls 30 issued U.S. and European patents, and has 200 patent applications pending, covering its technology, drug candidates, target genes and pipeline products.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing drug candidates that
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 The American Association for Homecare ... and Manufacturing has joined the AAHomecare Corporate Partner Program. ... Diamond have been actively involved in AAHomecare for ... has quickly grown into a major global manufacturer of ... allows AAHomecare to increase efforts on behalf of the ...
(Date:9/19/2014)... 19, 2014 Larry J. Merlo , President ... will speak before the National Press Club in ... recent move to stop selling tobacco products and its leadership ... health. "Dramatic changes in our health care system ... government," Merlo has said. "CVS Health has a truly unique ...
(Date:9/19/2014)... Sept. 19, 2014  Lpath, Inc. (NASDAQ: ... lipid-targeted therapeutics, announced today that it has entered ... of common stock and 3,605,042 unregistered warrants in ... for one registered share of common stock and ... of common stock will be $3.475.  The warrants ...
Breaking Medicine Technology:Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3
(Date:9/21/2014)... While public health authorities focus on the physical activity ... University of Montreal reveals that for children, playing has ... an activity that is fun, done alone or with ... or pleasure, but also to combat boredom, sadness, fear, ... of play, authorities put aside several aspects of play ...
(Date:9/21/2014)... Expert witness work is in! That ... its 2014 Expert Witness Fees & Practices Survey. With ... and compensation for qualified and credentialed expert witnesses has ... history. , The nearly 600 experts surveyed reported ... work, an increase of 3.2% from ExpertPages’ 2012 survey. ...
(Date:9/21/2014)... 2014 The asthma market saw ... it has become saturated with relatively efficacious standard ... (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and ... generic competition. However, the launch of seven novel ... therapies delivered by the next-generation inhalers will strongly ...
(Date:9/21/2014)... September 21, 2014 The Electronic ... and supports electronic medical records (EMR) and electronic ... federal healthcare legislation during the past five years ... during the five years to 2019. The 2009 ... Act established Medicare and Medicaid incentives to encourage ...
(Date:9/21/2014)... Market Research Report on ... 2009-2019 is a professional and in-depth market ... 49562-28-9) industry. The report firstly reviews the ... its classification, application and manufacturing technology.The report ... of Fenofibrate (CAS 49562-28-9) listing their product ...
Breaking Medicine News(10 mins):Health News:Narrow focus on physical activity could be ruining kids' playtime 2Health News:ExpertPages 2014 Survey Reports Expert Witness Hourly Fees Record All-Time Highs as Demand for Qualified Experts Continues to Grow 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 4Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4
... Medicare Strike Force Since March, WASHINGTON, Oct. 4 ... and operator of Direct Nursing Assistance Inc. of,Medicare fraud, ... and U.S. Attorney R. Alexander Acosta of the Southern ... trial, Rodolfo Aenlle, 47, was found guilty on all,counts ...
... IRIDEX,Corporation (Nasdaq: IRIX ) announced the ... the Company,s new independent auditor effective October,2, 2007. ... by the Audit Committee of the Company,s Board ... discussions with several,public accounting firms. BPM replaces PricewaterhouseCoopers ...
... in September Proving Successful, OWINGS MILLS, Md., Oct. ... that based on the current business outlook, the,Company is ... 31,2007. The Company expects to report revenue of $81 ... per diluted share. Previously, the Company,expected to report revenue ...
... part of what is ... nonprofit for teens., WILSONVILLE, Ore., Oct. 4 On Tuesday, October ... furniture,arcade games and supplies. These and other items, unused for at least ... the,Sexual Minority Youth Resource Center (SMYRC). Volunteer crews will move an ...
... Oct. 4 - A new American Heart,Association survey (1) shows consumer awareness ... an all-time high. But consumers still need,some key information to improve how ... the Bad Fats Are The survey shows that:, --While 92 ... jump from 84 percent in 2006 - only 21 percent ...
... revealing how toxic chemicals disrupt gene activity and other ... -- and why some individuals are particularly vulnerable. For ... more likely to experience side effects from certain medications, ... , How can this type of research -- known ...
Cached Medicine News:Health News:Miami Jury Convicts Medical Company Owner of Medicare Fraud 2Health News:Medifast Announces Updated Full Year 2007 Guidance 2Health News:Medifast Announces Updated Full Year 2007 Guidance 3Health News:Medifast Announces Updated Full Year 2007 Guidance 4Health News:Contents of the McGinnis Mansion Refurbishes Portland, Oregon Sexual Minority Youth Center 2Health News:Contents of the McGinnis Mansion Refurbishes Portland, Oregon Sexual Minority Youth Center 3Health News:Americans' Knowledge of Fats Growing But Still Insufficient 2Health News:Americans' Knowledge of Fats Growing But Still Insufficient 3
2.5% Soytone, 4.8% Yeast Extract, 0.025% Magnesium Sulfate, 130mM Calcium Chloride....
12% Tryptone, 24% Yeast Extract, 4.0% Glycerol. Supplied with 1 liter of 10x phosphate buffer (0190-1L)....
1.0% Casein digest (NZ amine), 0.5% Sodium Chloride, 0.5% Yeast Extract, 1.0% bacto casamino acids, 0.2% Mag. Sulfate....
S.O.C. Medium...
Medicine Products: